-+ 0.00%
-+ 0.00%
-+ 0.00%

Raymond James Initiates Coverage On Xilio Therapeutics with Outperform Rating, Announces Price Target of $16

Benzinga·10/21/2026 12:09:22
Listen to the news
Raymond James analyst Sean McCutcheon initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Outperform rating and announces Price Target of $16.